×

Gilead signs generic licensing deals for experimental Ebola drug

By Thomson Reuters Nov 16, 2026 | 4:08 PM

Nov 16 (Reuters) – Gilead Sciences said on Monday it had signed royalty-free deals with three generic drugmakers to make ​its experimental Ebola prevention drug ‌available in 127 mainly low- and lower-middle-income countries if it succeeds in trials and wins regulatory approvals.

Here are more details:

• The deals with Dr. ‌Reddy’s ​Laboratories, Eva Pharma and Ferozsons ⁠Laboratories cover obeldesivir, ⁠and include all African countries reporting cases in the current Ebola Bundibugyo outbreak

• Obeldesivir has shown activity against several Ebola-related ​viruses in preclinical studies but is not approved for any use in any ⁠country

• A late-stage trial ⁠is testing the drug in ​people at high risk after exposure. The deals ​are intended to line up manufacturing and ‌supply before trial results and regulatory filings

• Gilead is also expanding remdesivir licenses to cover Ebola-related diseases if trial results ⁠are positive and regulators approve the drug

• The company has donated more than 38,000 remdesivir vials ⁠to the ‌Democratic Republic of Congo, Uganda ⁠and Kenya, including more than ​2,000 ‌recently sent to Kenya for investigational ​treatment ⁠and post-exposure prevention

• Remdesivir is not approved to treat or prevent Ebola Bundibugyo disease, and its clinical effectiveness has not been established

(Reporting by Kunal Das in Bengaluru; Editing by ​Tasim Zahid)